Thomas Powles

Professor of Genitourinary Oncology

Queen Mary University of London

United Kingdom

Research Interests

Explore related searches

Professors in United Kingdom Professors in Immunology Immunology professors in United Kingdom

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Thomas Powles is a Professor of Genitourinary Oncology at Queen Mary University of London, UK. His research focuses on advanced urothelial cancer and renal cell carcinoma, particularly in the context of immunotherapy and targeted therapies. He has recently published articles on the efficacy of immune-checkpoint inhibitors, the impact of COVID-19 on kidney cancer treatment, and the role of radiomics in predicting patient outcomes.

Articles (10)

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Collaborators (3)

Michael Ong

University of Ottawa

CANADA

View details

Dónal Landers

The University of Manchester

UNITED KINGDOM

View details

Katherine Ordidge

Consultant Radiologist and Honorary Senior Clinical Lecturer

Barts Health NHS Trust

UNITED KINGDOM

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Thomas Powles

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

An adaptive, biomarker-directed platform study of durvalumab in combination with targeted therapies in advanced urothelial cancer.

First-line immune-checkpoint inhibitor combination therapy for chemotherapy-eligible patients with metastatic urothelial carcinoma: A systematic review and meta-analysis.

Impact of the first surge of the COVID-19 pandemic on a tertiary referral centre for kidney cancer.

Perioperative therapy in renal cancer in the era of immune checkpoint inhibitor therapy.

Radiomics for Renal Cell Carcinoma: Predicting Outcomes from Immunotherapy and Targeted Therapies-A Narrative Review.

Atezolizumab Versus Chemotherapy in Patients with Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: A Long-term Overall Survival and Safety Update from the Phase 3 IMvigor211 Clinical Trial.

Intratumoral CD103+ CD8+ T cells predict response to PD-L1 blockade.

Safety and Efficacy of Atezolizumab in Under Studied Populations with Pretreated Urinary Tract Carcinoma: Subgroup Analyses of the SAUL Study in Real-World Practice.

Should patients with low-risk renal cell carcinoma be followed differently after nephron-sparing surgery vs radical nephrectomy?

Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial.

Collaborators (3)

Michael Ong

Dónal Landers

Katherine Ordidge

Make your next move.